CEL-SCI CORP (CVM)
US1508376076 - Common Stock
CEL-SCI CORP
NYSEARCA:CVM (12/17/2024, 8:52:25 PM)
Premarket: 0.7996 +0.04 (+5.64%)0.7569
+0.11 (+16.45%)
Company Profile
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
Company Info
CEL-SCI CORP
Suite 802, 8229 Boone Blvd .
Vienna VIRGINIA 22182
P: 17035069460
CEO: Geert Kersten
Employees: 44
Website: https://cel-sci.com/
CVM News
6 days ago - ChartmillThese stocks are moving in today's after hours sessionStay updated with the stocks that are on the move in today's after-hours session.
6 days ago - CEL-SCI CorporationCEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Studya month ago - CEL-SCI CorporationU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 20252 months ago - CEL-SCI CorporationFDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients3 months ago - CEL-SCI CorporationCEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer3 months ago - CEL-SCI CorporationCEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and RadiationCVM Twits
Here you can normally see the latest stock twits on CVM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
